Encouraging response rates and high mobilization success with brentuximab vedotin plus GDP in adult relapsed/refractory classical Hodgkin lymphoma: A real-world study

Leukemia Research Reports · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles